This will play a video - couple on bicycles

TREAT MORE PATIENTS EVOLUT^TM TAVI PLATFORM FOR SSAS LOW RISK PATIENTS

A 2 YEAR FOLLOW UP

The 2 years¹ complete follow up has demonstrated:

TAVI noninferiority to surgery: primary endpoint 4.3% for TAVI vs 6.3% for SAVR.
Valve thrombosis rates remained low at two years.
Hemodynamics were significantly better for TAVI at all time points.

Animation of Evolut Pro TAVR showing the three leaflets opening and closing into the aorta

Superior HEMODYNAMICS

Evolut™ TAVI is the only TAVI device to demonstrate hemodynamic superiority in a low risk clinical trial vs. SAVR at two years.^*

Learn about HEMODYNAMICS

Indications, Safety, and Warnings

SUPERIOR
EFFECTIVE ORIFICE AREAS (EOA)

Evolut^TM TAVI
2.2 cm²
vs.
SAVR 2.0 cm²

SUPERIOR Gradients

Evolut^TM TAVI
9.0 mm Hg
vs.
SAVR 11.7 mm Hg

SAFE and EFFECTIVE

As demonstrated by all-cause mortality or disabling stroke, noninferior to SAVR at 24 months¹

Evolut^TM TAVI compared to SAVR

Evolut^TM TAVI showed lower mortality, fewer disabling strokes, and fewer heart failure rehospitalisations compared to SAVR²

Less Patient Prosthesis Mismatch.

Better Patient Outcomes.<sup>3,*</sup>

LEARN MORE ABOUT PPM

PATIENT PROSTHESIs
MIsMATCH MATTERS

Calculate your patient's risk of prosthesis mismatch.

PPM Calculator

EVOLUT^TM TAVI BICUSPID INDICATION

LEARN MORE

Contact Us to Learn More

*Indicates Required Field

Please select at least one option below:*

I would like to be contacted by a Medtronic representative

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

1. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.

2. Reardon MJ. The Evolut Low Risk Trial. Presented at ACC 2019; New Orleans, LA.

3. Herrmann HC, Daneshvar SA, Fonarow GC, et al. Prosthesis-Patient Mismatch in 62,125 Patients Following Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry. J Am Coll Cardiol. Published online September 18, 2018.

*Forrest J.K. M.D. On behalf of the Evolut Low Risk Investigators. The Evolut Low Risk Trial Complete 2-year follow-up. Presented at EuroPCR 2021.

SSAS = Symptomatic Severe Aortic Stenosis

TREAT MORE PATIENTS EVOLUTTM TAVI PLATFORM FOR SSAS LOW RISK PATIENTS

The 2 years1 complete follow up has demonstrated:

Superior HEMODYNAMICS

SUPERIOR EFFECTIVE ORIFICE AREAS (EOA)